Notice type: 3rd Party Publications
Problem Or Issue:
Important Safety Information communication from Novartis Ireland Ltd. on first reported case of progressive multifocal leukoencephalopathy (PML) in a multiple sclerosis patient taking Fingolimod without previous treatment by natalizumab or other immunosuppressive medicines.
Important Safety Information ¬- Gilenya (fingolimod)